[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"igan\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:igan":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,61,91,115,135,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100591638","phase-2-atacicept-in-multiple-glomerular-diseases-100591638",false,"NCT06983028","Atacicept in Multiple Glomerular Diseases","A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)","Inclusion Criteria:\n\n* Weight of at least 40 kg\n* On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease\n* Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.\n\nDiagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome\n\nFor patients enrolling in IgAN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy proven IgAN, IgAVN, or recurrent IgAN in kidney transplant\n* UPCR ≥ 0.5 g\u002Fg or UPE ≥ 0.5 g\u002Fday on 24h urine\n* eGFR≥ 20 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pediatric IgAN Cohorts (eligibility varies by cohort):\n\n* Age ≥ 2 years and \\\u003C 18 years\n* Biopsy proven IgAN or IgAVN\n* On stable prescribed regimen of RAASi (or SoC) for at least 8 weeks\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* eGFR≥ 30 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pMN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy-proven pMN\n* Anti PLA2R antibodies ≥ 25 RU\u002FmL\n* UPCR ≥ 1.5 g\u002Fg or UPE ≥ 1.5 g\u002Fd on 24h urine\n* At low risk for spontaneous remission (based on severity or duration of disease)\n\nFor patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):\n\n* Age ≥ 10 years\n* eGFR ≥30 mL\u002Fmin\u002F1.73m2\n* Adults with biopsy diagnosis of primary MCD or FSGS (adults) or children with challenging clinical course with steroids (frequenlty relapsing, steroid-dependent, or steroid-resistant)\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* Evidence of anti-nephrin antibodies\n\nKey Exclusion Criteria:\n\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)\n* Active viral or bacterial infections\n* Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study\n* Administration of live and live-attenuated vaccinations within 30 days prior to enrollment\n* Immunosuppressant medications within 4 weeks prior to dosing with atacicept (except transplant maintenance immunosuppression).\n* Known hypersensitivity to atacicept or any component of the formulated atacicept\n* Additional criteria apply to each cohort\u002Fdisease.","ALL","2 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.",[26,27,28,29,30],"pMN","IgAN","Nephrotic Syndrome","MCD","FSGS",[32,33,34,35,36,37,28,38,39,40,41,42,43,44,45,46,47],"IGA Glomerulonephritis","IGA Nephropathy","Iga Nephropathy 1","Immunoglobulin A Nephropathy Nephritis","IGA Type Nephropathy, IGA","Primary Membranous Nephropathy","Immunoglobulin A (IgA)","Immunoglobulin A vasculitis with nephritis (IgAVN)","Anti-PLA2R associated membranous nephropathy (PLA2R-MN)","Idiopathic\u002Fprimary nephrotic syndrome (MCD\u002FFSGS)","Glomerulonephritis","Nephritis","Autoimmune Diseases","Immune System Diseases","Kidney Diseases","Glomerulonephritis, IGA","RECRUITING","2026-06-23",{"date":51,"type":52},"2026-06-26","ACTUAL",{"date":54,"type":52},"2025-07-07",{"date":56,"type":20},"2027-11",{"name":58,"class":59},"Vera Therapeutics, Inc.","INDUSTRY",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100592125","phase-2-phase-2-study-of-adx-038-in-complement-mediated-kidney-disease-100592125","NCT06989359","Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease","A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease","Inclusion Criteria:\n\n* Mean eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73m2\n* Clinical evidence of active kidney disease\n* Treated with supportive care including an ACE inhibitor or ARB if applicable\n* Willing to receive required vaccinations\n* Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy\n\nExclusion Criteria:\n\n* Hereditary or acquired complement deficiency\n* Kidney transplant or renal replacement therapy\n* History of solid organ transplant\n* Other kidney disease\n* History of recurrent invasive infections\n* Received complement inhibitor treatments\n* Active systemic viral, bacterial, or fungal infection\n* Abnormal liver function","18 Years",{"count":70,"type":20},45,[23],"This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.",[27,74,75,76,77],"C3G","Complement-mediated Kidney Disease","IgA Nephropathy (IgAN)","IC-MPGN",[79,27,74,77,80],"IgA Nephropathy","complement-mediated kidney disease","2026-06-12",{"date":83,"type":52},"2026-06-16",{"date":85,"type":52},"2025-08-28",{"date":87,"type":20},"2029-06",{"name":89,"class":59},"ADARx Pharmaceuticals, Inc.",29,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100639148","phase-2-safety-and-efficacy-of-stl303-in-patients-with-primary-immunoglobulin-a-iga-nephropathy-100639148","NCT07606352","Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy","A Multicenter, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy","Inclusion Criteria:\n\n1. Male and female patients aged 18 years and older, with primary IgAN confirmed by renal biopsy:\n2. eGFR (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula) greater than or equal to 30 mL\u002Fmin\u002F1.73 m2 at screening and after completion of run-in.\n3. UPCR greater than or equal to 0.75 g\u002Fg at screening and after completion of run-in.\n4. Vaccinated against Neisseria meningitidis and Streptococcus pneumoniae before the first dose.\n5. Have received stable treatment with RASis (ACEi or ARB) at the maximum recommended dose or MTD for at least 90 days prior to the first dose.\n6. If the patient has been treated with SGLT2i, diuretics, other antihypertensive treatments, ERA, and\u002For hydroxychloroquine for IgAN prior to the first dose, the drug should also be used stably for at least 90 days.\n\nExclusion Criteria:\n\n1. Secondary IgAN or unclear exclusion of secondary causes.\n2. Rapidly progressive IgAN (eGFR decline greater than or equal to 50% in 3 months, or less than 50% but at high risk).\n3. Other systemic diseases causing proteinuria\u002FCKD or severe urinary obstruction.\n4. Known or suspected immunodeficiency or hereditary complement deficiency.\n5. Any organ transplant recipients except corneal.\n6. Poorly controlled blood pressure (SBP greater than 150 or DBP great than 90).\n7. Use of immunosuppressive drugs within 90 days or 5 half-lives.\n8. Prior oral budesonide (Nefecon\u002FTarpeyo\u002FKinpeygo) within 6 months.\n9. Prior complement inhibitors within 30 days, 5 half-lives, or residual effect period.\n10. Major systemic diseases preventing participation (e.g., NYHA IV, severe pulmonary disease).\n11. Significantly abnormal liver function (greater than 3× ULN enzymes or greater than 2× ULN bilirubin).\n12. QTcF greater than 500 ms.\n13. History of malignancy within 5 years (exceptions apply).\n14. History of meningococcal, pneumococcal, or Hib infection.\n15. Chronic\u002Frecurrent infections in past year (e.g., liver abscess, pyelonephritis).\n16. Active systemic infections within 2 weeks or fever greater than 38°C within 7 days.",{"count":99,"type":20},15,[23],"This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.",[27],[27],"NOT_YET_RECRUITING","2026-05-24",{"date":107,"type":52},"2026-05-28",{"date":109,"type":20},"2026-06",{"date":111,"type":20},"2027-09",{"name":113,"class":59},"Sitala Bio LTD",3,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":131,"leadSponsor":133,"locationsCount":60},"100631588","phase-2-fxs6837-for-the-treatment-of-igan-patients-100631588","NCT07502638","FXS6837 for the Treatment of IgAN Patients","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of FXS6837 in IgAN Patients","Inclusion criteria:\n\n1. Adult male or female patients aged ≥18 years with biopsy-confirmed primary IgA nephropathy (IgAN), meeting all of the following:\n\n   1. A qualifying renal biopsy performed within the past 8 years;\n   2. ≤50% tubulointerstitial fibrosis;\n   3. Crescent formation present in ≤50% of glomeruli;\n   4. If a historical biopsy is not available, a biopsy may be performed during screening.\n2. Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m² at screening and at the end of the run-in period.\n3. Urine protein-to-creatinine ratio (UPCR) ≥0.75 g\u002Fg at screening and at the end of the run-in period.\n4. Vaccination against Neisseria meningitidis and Streptococcus pneumoniae is required prior to initiation of study treatment. If not previously vaccinated or if a booster is required, 5. vaccination should be administered according to local regulations at least 2 weeks prior to first dose. If treatment must begin earlier, prophylactic antibiotic therapy should be initiated.\n5. Patients must have received a stable dose of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), at the locally approved maximum daily dose or maximally tolerated dose (per investigator judgment), for at least 90 days prior to first dose. If receiving sodium-glucose cotransporter-2 inhibitors (SGLT2i), endothelin receptor antagonists (ERA), or hydroxychloroquine, doses must also be stable for at least 90 days prior to first dose (per investigator judgment).\n\nExclusion criteria:\n\n1. Secondary IgA nephropathy (IgAN), as defined by the investigator.\n2. Rapidly progressive IgAN, defined as ≥50% decline in eGFR (CKD-EPI) within 3 months, or \\\u003C50% decline but considered by the investigator to be at risk of rapid renal function deterioration.\n3. Other systemic diseases associated with proteinuria or chronic kidney disease (e.g., diabetic nephropathy, lupus nephritis, ANCA-associated vasculitis), or severe urinary tract obstruction or dysuria.\n4. Prior treatment with immunosuppressive agents, including but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF), mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids within 90 days (or 5 half-lives, whichever is longer) prior to first dose.\n5. Prior treatment with oral budesonide (Nefecon®) within 6 months prior to first dose.\n6. Prior treatment with other complement inhibitors within 30 days (or 5 half-lives, whichever is longer) prior to first dose.\n7. Positive test results for HIV; active syphilis infection; chronic hepatitis B infection (HBsAg positive with HBV DNA \\> lower limit of quantification \\[LOQ\\]); or hepatitis C infection (positive HCV antibody with detectable HCV RNA).\n8. Active tuberculosis at screening.\n9. Clinically significant abnormal liver function at screening, defined as any of the following: ALT, AST, GGT, or ALP \\>3 × upper limit of normal (ULN), or total bilirubin \\>2 × ULN.\n10. History of meningococcal infection.\n11. Active systemic bacterial, viral (including COVID-19), or fungal infection within 14 days prior to first dose, or body temperature \\>38°C within 7 days prior to first dose.",{"count":123,"type":20},60,[23],"This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.",[27],"2026-03-27",{"date":129,"type":52},"2026-03-31",{"date":129,"type":20},{"date":132,"type":20},"2027-11-14",{"name":134,"class":59},"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":68,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":146,"conditions":147,"keywords":153,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100594831","phase-3-study-of-ravulizumab-in-pediatric-participants-with-primary-igan-100594831","NCT07024563","Study of Ravulizumab in Pediatric Participants With Primary IgAN","A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to \u003C 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)","Inclusion Criteria:\n\n* Participant must be 2 to \\\u003C 18 years of age at the time of signing the informed consent or assent.\n* Stable and maximum allowed or tolerated RASI (ACEI and\u002For ARB) dose for ≥ 3 months prior to Screening with no planned change during Screening through Week 106.\n* UPCR ≥ 1.0 g\u002Fg from the mean of 3 first morning voids (FMV) collected within 1 week during the Screening Period\n* Estimated GFR ≥ 30 mL\u002Fmin\u002F1.73 m2 during Screening\n* Meningococcal infection vaccine\n* Haemophilus influenzae type b and Streptococcus pneumoniae vaccine\n* Participants who are receiving SGLT2i, DEARA (eg, sparsentan), MRA, ERA, or GLP-1 agonists must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to Screening with no planned change in dose through Week 34.\n* Established diagnosis of primary IgAN diagnosis based on kidney biopsy within 3 years prior to Screening or during the Screening Period\n\nExclusion Criteria:\n\n* Diagnosis of rapidly progressive glomerulonephritis\n* Secondary forms of IgAN not in the context of primary IgAN or IgAV\n* Concomitant clinically significant renal disease other than IgAN or IgAVN\n* Clinical remission of IgAN\u002FIgAVN or clinically significant improvement in proteinuria within the last 6 months.\n* Uncontrolled diabetes mellitus with HbA1c \\> 8.5%\n* History of kidney transplant or planned kidney transplant during the Primary Evaluation Period.\n* History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant\n* Splenectomy or functional asplenia\n* Participants with nephrotic syndrome receiving albumin infusions or with acute kidney injury requiring dialysis within the last 6 months prior to Screening.\n* Hemolytic uremic syndrome diagnosed any time prior to Screening.\n* Planned urological surgery expected to influence kidney function within the study time frame.\n* Congenital immunodeficiency\n* Active systemic bacterial, viral, or fungal infection within 14 days prior to enrollment\n* Received biologics for the treatment of IgAN or IgAVN within≤ 6 months prior to Screening",{"count":143,"type":20},24,[145],"PHASE3","The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.",[27,148,149,150,151,152],"IgAVN","Immunoglobulin A Nephropathy","Immunoglobulin A Vasculitis Associated Nephritis","Henoch-schonlein Purpura Nephritis","IgA Vasculitis",[154,27,148,155,156,157,149,150],"ravulizumab","pediatric","proteinuria","glomerulonephropathy","2026-03-16",{"date":160,"type":52},"2026-03-17",{"date":162,"type":52},"2025-06-14",{"date":164,"type":20},"2029-11-27",{"name":166,"class":59},"Alexion Pharmaceuticals, Inc.",14,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":60},"100629435","phase-2-efficacy-and-safety-study-of-hs-10542-for-iga-nephropathy-100629435","NCT07474636","Efficacy and Safety Study of HS-10542 for IgA Nephropathy","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of HS-10542 Capsules in Primary Immunoglobulin A (IgA) Nephropathy","HS-10542","Inclusion Criteria:\n\n1. Participant is a male or female≥18 years and≤74 years of age at the time of signing the informed consent.\n2. Body weight≥35kg, BMI\\\u003C37.5kg\u002Fm2.\n3. Primary IgA nephropathy was confirmed by renal biopsy within 8 years.\n4. 24-hour urine protein excretion≥1.0g\u002F24h, or UPCR≥0.8g\u002Fg at screening and prior to randomization.\n5. eGFR≥30 ml\u002Fmin\u002F1.73m2 at screening and prior to randomization；\n6. A fertile female participant or a male participant whose partner is a fertile female, who has not had a fertility, sperm\u002Fegg donation plan and voluntarily takes highly effective contraceptive measures (including the partner).\n7. All participants received RAS blocker treatment at least for 12 weeks, or demonstrated intolerance to RAS blockers, but has received SGLT2 inhibitors, endothelin receptor antagonists, or a mineralocorticoid receptor antagonist for at least 12 weeks, and have achieved the maximum recommended dose according to the product label or the maximum tolerated dose with stable dosing for at least 4 weeks prior to randomization.\n8. Participants should be able to complete vaccinations against Neisseria meningitidis (types A, C, Y, and W-135) and streptococcus pneumoniae at least 2 weeks prior to the first dose.\n9. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. Participants with a history of severe allergies to drugs, food or the environment, or allergic to any RAS blockers, investigational products, or components as evaluated by the investigator;\n2. Participant has secondary forms of IgAN as defined by investigator (eg, IgA vasculitis nephritis, SLE) or participant has nephrotic syndrome (defined as proteinuria\\>3.5 g\u002Fday and serum albumin\\\u003C3.0 g\u002FdL, with or without edema);\n3. IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%;\n4. Patients with concomitant immunodeficiency disorders; or those with other systemic diseases assessed by the investigator as potentially causing proteinuria (e.g., diabetic nephropathy, autoimmune diseases, ANCA-associated vasculitis, etc.);\n5. Any organ transplant recipient, including those who have undergone solid organ transplants, bone marrow transplants and haematopoietic stem cell transplants.\n6. Participants with a medical history of invasive infections caused by capsulated bacteria, including Neisseria meningitidis and Streptococcus pneumoniae;\n7. Participants with chronic recurrent infections within 1 year prior to screening, such as liver abscess and pyelonephritis; Or participants with active infection who requiring intravenous antibiotic therapy within 2 weeks prior to randomization;\n8. Participants have a history of malignancy (except of radical excision of basal cell or squamous cell skin cancer, or cervical carcinoma in situ.), Participants with prior malignancy who have been documented to be cancer-free for≥5 years may be enrolled;\n9. Participants with a history of severe trauma or major surgery within 12 weeks prior to screening, or who plan to undergo surgery during the study period;\n10. Participants with a history of blood donation or a history of severe blood loss (≥400 mL blood loss) within 12 weeks prior to screening, or who have received blood transfusions within 12 weeks prior to screening;\n11. Participants had received systemic glucocorticoid therapy, immunosuppressive agents (e.g. mycophenolate mofetil or calcineurin inhibitors), Chinese patent medicines with immunosuppressive properties (e.g. Tripterygium wilfordii tablets), or renin inhibitors within 12 weeks of randomisation. Alternatively, they were assessed by the investigator as potentially requiring such treatments during the study period.\n12. Participants had received treatment with biologics (e.g. telitacicept, atacicept, povetacicept, sibeprenlimab, CD38 monoclonal antibodies), or with budesonide enteric capsules (NEFECON) or cytokine inhibitors, as well as other products related to the complement pathway (e.g. eculizumab, ravulizumab and avacopan), which were not included in the investigational drug of this study within 6 months prior to randomisation, or participants had received iptacopan within 12 weeks prior to randomization;\n13. Participants have a history of gastrointestinal surgery that may significantly affect the absorption, distribution, metabolism or excretion of drugs. Or have a history of severe gastrointestinal disease, or be experiencing symptoms of dysphagia or recurrent vomiting that cause difficulty eating or taking medication.\n14. Participants with poorly controlled severe systemic diseases at screening, including, but not limited to, severe hypertension (SBP≥180 mmHg and\u002For DBP110 mmHg), severe cardiac disease, pulmonary disease, hepatic disease or haematological disorders, which significantly increase the participant's safety risk as assessed by the investigator;\n15. Participants with a history of tuberculosis, or who have current symptoms, signs, imaging or laboratory evidence of active tuberculosis, or who have a positive IGRA tuberculosis infection screening test result (except the participants who have medical documented evidence of having received standardized preventive anti-tuberculosis treatment within the 5 years prior to screening);\n16. ALT or AST or total bilirubin levels\\>3×ULN at screening;\n17. Hb\\\u003C90 g\u002FL or PLT\\\u003C80×109\u002FL at screening;\n18. HBsAg positive; or HBsAg negative but HBcAb positive with HBV-DNA quantitative results exceeding the ULN defined by the local lab; HCV antibody positive with HCV-RNA quantitative results exceeding the ULN defined by the local lab; HIV antibody positive;\n19. HBA1C≥9.0% at screening;\n20. Participants who have participated in a clinical trial of any drug or medical device within 12 weeks prior to randomization and are expected to have residual effects of the investigational treatment (as determined by the investigator), or in any drug clinical trial within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to screening, or who participated in a clinical trial of oligonucleotide drugs within 1 year prior to randomization;\n21. Women who are pregnant or breastfeeding prior to randomization;\n22. Drug or alcohol abuse within 6 months prior to randomization;\n23. Any illness or condition that the investigator deems likely to increase the risk of the trial, affect participants adherence to the protocol or prevent them from completing it.","74 Years",{"count":178,"type":20},90,[23],"This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.",[27,182,183],"Immunoglobulin A Nephropathy (IgAN)","Glomerular Disease",[27,149,174],"2026-03-11",{"date":158,"type":52},{"date":160,"type":20},{"date":189,"type":20},"2028-01-30",{"name":191,"class":59},"Jiangsu Hansoh Pharmaceutical Co., Ltd."]